AIDS, Avian flu, SARS, MERS, Ebola, Zika… what next?
Emerging infections have threatened humanity since times immemorial. The dramatic anthropogenic, behavioral and social changes that have affected humanity and the environment in the past century have accelerated the intrusion of novel pathogens into the global human population, sometimes with devast...
Published in: | Vaccine |
---|---|
Main Authors: | , |
Format: | Text |
Language: | English |
Published: |
Published by Elsevier Ltd.
2017
|
Subjects: | |
Online Access: | http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7115365/ http://www.ncbi.nlm.nih.gov/pubmed/28633891 https://doi.org/10.1016/j.vaccine.2017.04.082 |
id |
ftpubmed:oai:pubmedcentral.nih.gov:7115365 |
---|---|
record_format |
openpolar |
spelling |
ftpubmed:oai:pubmedcentral.nih.gov:7115365 2023-05-15T15:34:21+02:00 AIDS, Avian flu, SARS, MERS, Ebola, Zika… what next? Reperant, Leslie A. Osterhaus, Albert D.M.E. 2017-08-16 http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7115365/ http://www.ncbi.nlm.nih.gov/pubmed/28633891 https://doi.org/10.1016/j.vaccine.2017.04.082 en eng Published by Elsevier Ltd. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7115365/ http://www.ncbi.nlm.nih.gov/pubmed/28633891 http://dx.doi.org/10.1016/j.vaccine.2017.04.082 © 2017 Published by Elsevier Ltd. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. Article Text 2017 ftpubmed https://doi.org/10.1016/j.vaccine.2017.04.082 2020-04-05T01:02:21Z Emerging infections have threatened humanity since times immemorial. The dramatic anthropogenic, behavioral and social changes that have affected humanity and the environment in the past century have accelerated the intrusion of novel pathogens into the global human population, sometimes with devastating consequences. The AIDS and influenza pandemics have claimed and will continue to claim millions of lives. The recent SARS and Ebola epidemics have threatened populations across borders. The emergence of MERS may well be warning signals of a nascent pandemic threat, while the potential for geographical spread of vector-borne diseases, such as Zika, but also Dengue and Chikungunya is unprecedented. Novel technologies and innovative approaches have multiplied to address and improve response preparedness towards the increasing yet unpredictable threat posed by emerging pathogens. Text Avian flu PubMed Central (PMC) Vaccine 35 35 4470 4474 |
institution |
Open Polar |
collection |
PubMed Central (PMC) |
op_collection_id |
ftpubmed |
language |
English |
topic |
Article |
spellingShingle |
Article Reperant, Leslie A. Osterhaus, Albert D.M.E. AIDS, Avian flu, SARS, MERS, Ebola, Zika… what next? |
topic_facet |
Article |
description |
Emerging infections have threatened humanity since times immemorial. The dramatic anthropogenic, behavioral and social changes that have affected humanity and the environment in the past century have accelerated the intrusion of novel pathogens into the global human population, sometimes with devastating consequences. The AIDS and influenza pandemics have claimed and will continue to claim millions of lives. The recent SARS and Ebola epidemics have threatened populations across borders. The emergence of MERS may well be warning signals of a nascent pandemic threat, while the potential for geographical spread of vector-borne diseases, such as Zika, but also Dengue and Chikungunya is unprecedented. Novel technologies and innovative approaches have multiplied to address and improve response preparedness towards the increasing yet unpredictable threat posed by emerging pathogens. |
format |
Text |
author |
Reperant, Leslie A. Osterhaus, Albert D.M.E. |
author_facet |
Reperant, Leslie A. Osterhaus, Albert D.M.E. |
author_sort |
Reperant, Leslie A. |
title |
AIDS, Avian flu, SARS, MERS, Ebola, Zika… what next? |
title_short |
AIDS, Avian flu, SARS, MERS, Ebola, Zika… what next? |
title_full |
AIDS, Avian flu, SARS, MERS, Ebola, Zika… what next? |
title_fullStr |
AIDS, Avian flu, SARS, MERS, Ebola, Zika… what next? |
title_full_unstemmed |
AIDS, Avian flu, SARS, MERS, Ebola, Zika… what next? |
title_sort |
aids, avian flu, sars, mers, ebola, zika… what next? |
publisher |
Published by Elsevier Ltd. |
publishDate |
2017 |
url |
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7115365/ http://www.ncbi.nlm.nih.gov/pubmed/28633891 https://doi.org/10.1016/j.vaccine.2017.04.082 |
genre |
Avian flu |
genre_facet |
Avian flu |
op_relation |
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7115365/ http://www.ncbi.nlm.nih.gov/pubmed/28633891 http://dx.doi.org/10.1016/j.vaccine.2017.04.082 |
op_rights |
© 2017 Published by Elsevier Ltd. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
op_doi |
https://doi.org/10.1016/j.vaccine.2017.04.082 |
container_title |
Vaccine |
container_volume |
35 |
container_issue |
35 |
container_start_page |
4470 |
op_container_end_page |
4474 |
_version_ |
1766364781988544512 |